Introduction
This study analyzes Pfizer’s financial outcomes from the past three years, highlighting its status as a prominent player in the pharmaceutical sector and its listing on a U.S. stock exchange (Yahoo Finance, 2024). A comprehensive analysis of the annual financial documents is conducted to detect notable variations in its financial standing. This review thoroughly examines Pfizer’s financial reports to pinpoint significant changes in its assets, liabilities, and shareholder equity. Additionally, key financial metrics, including return on equity, the debt-to-equity ratio, quick ratio, current ratio, and net profit margin, will be analyzed over two consecutive years.
Financial Statement Overview
The analyzed balance sheet showcases Pfizer’s fiscal evolution over three years, with significant changes in financial accounts highlighting the firm’s tactical fiscal governance and business modifications. A steady rise in overall assets is observed, from $154.229 billion in 2020 to $197.205 billion by the close of 2022, signaling Pfizer’s vigorous pursuit of asset accumulation (Pfizer, 2023).
Noteworthy is the increase in long-term assets from $119.161 billion in 2020 to $145.944 billion in 2022, reflecting Pfizer’s commitment to investing in long-lasting assets, such as property, plant, and equipment (PPE) and non-physical assets (Pfizer, 2023). In contrast, a decline in short-term assets, falling from $59.693 billion in 2021 to $51.259 billion in 2022, with cash and short-term investments decreasing from $31.069 billion to $22.732 billion, may indicate strategic shifts toward reinforcing long-term asset value or other notable disbursements (Pfizer, 2023).
An examination of liabilities and shareholder equity provides revealing insights into Pfizer’s fiscal wellness. A modest decrease in total liabilities, from $104.014 billion in 2021 to $101.289 billion in 2022, along with a slight dip in short-term liabilities, suggests proficient liability management (Pfizer, 2023). Impressively, there has been a considerable increase in shareholder equity, from $63.473 billion in 2020 to $95.916 billion in 2022 (Pfizer, 2023), indicative of Pfizer’s ability to enhance investor wealth, potentially through higher earnings retention or increased equity capital, thereby reinforcing its financial bedrock.
Financial Ratio Analysis
The analysis of financial ratios provided insight into Pfizer’s financial health over the three years from 2020 to 2022. A total of 5 ratios were calculated: debt-to-equity ratio, current ratio, return on equity, quick ratio, and net profit margin. These ratios are outlined in Table 1 below.
Table 1. Key financial ratios of Pfizer between 2020 and 2022
The Debt-to-Equity Ratio measures a firm’s financial leverage by reflecting the proportion of debt and shareholders’ equity used to finance its assets. Pfizer exhibited a relatively high ratio of 1.43 in 2020, indicating a tendency towards debt financing. By 2022, this figure had fallen to 1.06, revealing a substantial shift towards equity, suggesting Pfizer’s strategic efforts to consolidate its financial structure by either reducing debt levels or augmenting shareholder equity, a trend considered favorable for fiscal solidity (Schuster et al., 2021).
The Current Ratio, a metric for evaluating a company’s capacity to meet its short-term debts with assets due within a year, declined at Pfizer from 1.40 in 2021 to 1.22 in 2022. A ratio exceeding 1 indicates that the company has adequate current assets to meet its short-term debt obligations, which bodes well for its immediate financial health (Schuster et al., 2021).
The dip, however, may signal an uptick in short-term debt or a reduction in current assets, suggesting a liquidity squeeze. The Quick Ratio, a stricter liquidity measure that excludes inventory, also decreased from 1.19 in 2021 to an even 1.00 in 2022 for Pfizer, suggesting that it holds just sufficient liquid assets to cover its immediate liabilities, presenting a picture of stable but tighter liquidity (Schuster et al., 2021).
Return on Equity (ROE) showcases the efficiency with which a company capitalizes on shareholders’ investments to generate profits. Pfizer’s ROE impressively more than doubled from 0.14 in 2020 to 0.33 in 2022, highlighting enhanced returns on equity capital, which can be enticing for investors (Schuster et al., 2021). Furthermore, the Net Profit Margin, which indicates the portion of revenue converted into profits, has steadily risen from 21.99% in 2020 to 31.27% in 2022. This progression suggests that Pfizer is not just increasing its revenue, but is also more effectively managing expenses and enhancing profit conversion from sales.
Conclusion
In conclusion, the meticulous examination of Pfizer’s financial statements over three years reveals a deliberate expansion of its asset base, coupled with judicious oversight of its liabilities, culminating in a strengthened equity position. The financial ratios highlight Pfizer’s dedication to maintaining fiscal stability, showcasing notable strides in profitability and operational adeptness. Through debt reduction, liquidity preservation, and marked improvements in both return on equity and net profit margins, Pfizer demonstrates solid financial health and a proactive strategy to maintain its competitive position in the pharmaceutical sector.
References
Pfizer. (2023). Annual Report 2022.
Schuster, P., Heinemann, M., & Cleary, P. (2021). Management Accounting. Springer International Publishing.
Yahoo Finance. (2024). Pfizer (PFE).